English
Chinese
Cart
This product is not clubbable with other items in cart. Please remove this or other items to proceed further.
Deleting
No Items In Cart
SCHOTT adaptiQ® Vials
Overview
Product Attributes
Downloadable Resources
adaptiQ® and SCHOTT iQ® are registered trademarks of SCHOTT AG.
NovaPure® and Flip-Off® are registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
NovaPure® and Flip-Off® are registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
Related Blogs
March 16, 2021
Addressing the Challenges in Research for Biologics
In recent years, an increasing variety of biologic drugs have been developed including vaccines, recombinant proteins, gene and cell therapies. In China, this increased demand will be reflected in a significant growth in the size of the bio-pharmaceutical industry. As a result, the Chinese government is increasing its investment.
April 02, 2021
FluroTec™ Barrier Films – Protecting Your Biologics
There is no doubt biologics and biosimilars will remain one of the hot topics in 2021. This is due to the pandemic period of SARS-CoV-2 and the innovative treatments and vaccines that are under development at accelerated speed. Several questions can arise regarding selection of the proper primary package system for a biologic/biosimilar.
March 10, 2021
Biosimilars Market Survey Brings Insight to Most Important Containment and Support Service Needs
Biosimilar development and approvals have been accelerated over the last several years. The rapid uptake in this category is due in large part to clarity on regulatory pathways that demonstrate interchangeability with the reference product and key patent expiry over the next decade. By 2025 injectable biosimilars are projected to comprise almost 50% of the accessible biologics market1. West recently conducted a survey of biosimilar companies to better understand their top needs for packaging and support services during drug development.
March 16, 2021
Addressing the Challenges in Research for Biologics
In recent years, an increasing variety of biologic drugs have been developed including vaccines, recombinant proteins, gene and cell therapies. In China, this increased demand will be reflected in a significant growth in the size of the bio-pharmaceutical industry. As a result, the Chinese government is increasing its investment.
April 02, 2021
FluroTec™ Barrier Films – Protecting Your Biologics
There is no doubt biologics and biosimilars will remain one of the hot topics in 2021. This is due to the pandemic period of SARS-CoV-2 and the innovative treatments and vaccines that are under development at accelerated speed. Several questions can arise regarding selection of the proper primary package system for a biologic/biosimilar.
March 10, 2021
Biosimilars Market Survey Brings Insight to Most Important Containment and Support Service Needs
Biosimilar development and approvals have been accelerated over the last several years. The rapid uptake in this category is due in large part to clarity on regulatory pathways that demonstrate interchangeability with the reference product and key patent expiry over the next decade. By 2025 injectable biosimilars are projected to comprise almost 50% of the accessible biologics market1. West recently conducted a survey of biosimilar companies to better understand their top needs for packaging and support services during drug development.
